MYCN and neuroblastoma: The decrease in MYCN expression after dinutuximab treatment is significant, and may explain one mechanism behind the clinical benefit observed from using anti‐GD2 immunotherapy.38 Future studies will need to investigate the significance of this effect, particularly examining how dinutuximab or anti‐GD2 therapy could change the risk profile of MYCN‐amplified neuroblastoma.